Last $91.45 USD
Change Today -0.20 / -0.22%
Volume 1.1M
FRX On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 4:15 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

forest laboratories inc (FRX) Snapshot

Open
$91.91
Previous Close
$91.65
Day High
$92.19
Day Low
$90.21
52 Week High
02/26/14 - $100.88
52 Week Low
04/24/13 - $36.41
Market Cap
24.8B
Average Volume 10 Days
2.6M
EPS TTM
$0.79
Shares Outstanding
271.0M
EX-Date
--
P/E TM
116.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for FOREST LABORATORIES INC (FRX)

forest laboratories inc (FRX) Related Businessweek News

View More BusinessWeek News

forest laboratories inc (FRX) Details

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company’s products include Linzess for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation; Tudorza Pressair, an antimuscarinic agent to treat bronchospasm associated with chronic obstructive pulmonary disease; Viibryd for the treatment of adults with major depressive disorder (MDD); and Daliresp, a phosphodiesterase-4 enzyme inhibitor to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD. Its products also comprise Teflaro for the treatment of adults with skin and skin structure infections; Bystolic to treat hypertension; Namenda and Namenda XR for the treatment of moderate and severe Alzheimer's disease; Savella to treat fibromyalgia; and Colobreathe, a dry powder inhaler for the treatment of chronic lung infections. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; Cariprazine that is in Phase III clinical trials to treat acute exacerbation of schizophrenia and acute mania associated with bipolar disorder; ceftazidime/avibactam, which is under Phase III clinical trials for intra-abdominal infections and for complicated urinary tract infections; and Cebranopadol (GRT 6005) that has completed Phase II clinical trials for moderate to severe chronic pain conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. It has collaborative licensing option agreement with Trevena for the development of TRV027 for the treatment of acute decompensated heart failure; and collaboration agreement with Ironwood develop and commercialize Linzess. The company was founded in 1956 and is headquartered in New York, New York.

5,800 Employees
Last Reported Date: 05/23/13
Founded in 1956

forest laboratories inc (FRX) Top Compensated Officers

Non-Executive Chairman and Senior Advisor
Total Annual Compensation: $1.3M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $658.5K
Executive Vice President of International, St...
Total Annual Compensation: $709.2K
Chief Medical Officer, Executive Vice Preside...
Total Annual Compensation: $600.3K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $486.3K
Compensation as of Fiscal Year 2013.

forest laboratories inc (FRX) Key Developments

Forest Laboratories Inc. and Gedeon Richter Plc. Announce Positive from Phase IIb Study

Forest Laboratories Inc. and Gedeon Richter plc announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine as adjunctive treatment in adult patients with Major Depressive Disorder (MDD) who have demonstrated an inadequate response to antidepressant therapy (ADT). The trial consisted of three treatment groups, cariprazine 1.0 - 2.0 mg/day + ADT and cariprazine 2.0 -4.5 mg/day + ADT, and placebo + ADT. The group who received cariprazine 2.0 - 4.5 mg/day + ADT demonstrated statistically significant improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) total score versus placebo at 8 weeks, the primary endpoint. Phase IIb Study: This international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose, 8-week Phase IIb study evaluated the efficacy, safety, and tolerability of cariprazine as adjunctive treatment in adult patients with MDD who demonstrated an inadequate response to ADT. Eligible patients were those who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for MDD, had a minimum score of 22 on the MADRS scale, and had an ongoing inadequate response to ADT. Following a 7-14 day screening and washout period, a total of 819 patients between 18 and 65 years of age were randomized to one of three treatment groups (either cariprazine 1.0 -2.0 mg/day + ADT, cariprazine 2.0 -4.5 mg/day + ADT, or placebo + ADT) followed by a 1-week safety follow-up period. The primary endpoint was defined as change from baseline to end of week 8 in the MADRS total score. Statistically significant improvement in the MADRS total score was observed in the cariprazine 2.0 -4.5 mg/day + ADT group relative to the placebo + ADT treatment group (cariprazine 2.0 -4.5 mg/day + ADT: -2.2, p=0.0114 and cariprazine 1.0 -2.0 mg/day + ADT: -0.9, p=0.2404) by MMRM analysis.

Forest Laboratories Inc. to Eliminate 10% to 20% of its Workforce on Long Island

Forest Laboratories Inc. has begun a cost-cutting effort that could lead to the elimination of 10% to 20% of its workforce on Long Island. The company employs more than 600 people in its Commack and Hauppauge locations. The company declined to give an exact number of jobs that would be lost locally. The cuts are part of Forest's 'Project Rejuvenate,' a plan announced in December 2013 to reduce costs and streamline operations.

Forest Laboratories Inc. and Adamas Pharmaceuticals, Inc. Announce Forest's Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer's Disease

Forest Laboratories, Inc. and Adamas Pharmaceuticals Inc. announced Forest's submission of a New Drug Application (NDA) to the Food and Drug Administration for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer's type. The concurrent use of memantine and donepezil is a well-established treatment option for patients with moderate to severe dementia related to Alzheimer's disease. Using the two drugs together appears to provide benefit over using acetylcholinesterase inhibitors alone. Reducing the number of pills by offering patients a fixed-dose combination helps lessen the daily medication burden and could improve patient adherence and compliance. The memantine ER-donepezil HCl FDC is a once-daily oral capsule for patients currently taking memantine (10 mg twice daily or 28 mg extended-release once-daily) and donepezil 10 mg. In addition, the capsules can be opened to allow the contents to be sprinkled on applesauce to facilitate dosing for patients who may have difficulty swallowing. The New Drug Application consisted of two dosage strengths, 28mg/10mg (memantine extended release/donepezil) and 14mg/10mg (memantine extended release/donepezil) for patients with severe renal impairment. Memantine ER is the active ingredient in the currently marketed NAMENDA XR(R), which is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Donepezil is the active ingredient in ARICEPT(R), which is indicated for the treatment of mild to severe dementia of the Alzheimer's type. Forest and Adamas collaborated on the development of the fixed dose combination and Forest will have exclusive US commercialization rights while Adamas will retain exclusive commercialization rights outside of the US. The FDC product is covered by multiple Adamas patents and a Forest patent that extend to 2029.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRX:US $91.45 USD -0.20

FRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $61.86 USD -0.16
Grifols SA €38.25 EUR -0.05
Perrigo Co PLC $147.70 USD -2.23
Shire PLC 3,248 GBp +59.00
UCB SA €59.57 EUR -0.10
View Industry Companies
 

Industry Analysis

FRX

Industry Average

Valuation FRX Industry Range
Price/Earnings 100.0x
Price/Sales 7.3x
Price/Book 4.1x
Price/Cash Flow 158.5x
TEV/Sales 6.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOREST LABORATORIES INC, please visit www.frx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.